Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines

BACKGROUND: Tamoxifen is the standard endocrine therapy for ER+ breast cancer; however, many women still relapse after long-term therapy. 3-Bromopyruvate, a glycolytic inhibitor, has shown high selective anti-tumor activity in vitro, and in vivo. The aim of this study was to evaluate the possible au...

Descripción completa

Detalles Bibliográficos
Autores principales: Attia, Yasmin M., EL-Abhar, Hanan S., Al Marzabani, Mahmoud M., Shouman, Samia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630933/
https://www.ncbi.nlm.nih.gov/pubmed/26526196
http://dx.doi.org/10.1186/s12885-015-1850-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630933/
https://www.ncbi.nlm.nih.gov/pubmed/26526196
http://dx.doi.org/10.1186/s12885-015-1850-4

Ejemplares similares